Navigation Links
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016
Date:12/18/2016

NEW YORK, Dec. 17, 2016 /PRNewswire/ -- Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016, provides an overview of the Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Predisposing factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA may be managed by the use of antibiotics and by maintaining hygienic conditions.


Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 4 respectively.Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections.

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read the full report: http://www.reportlinker.com/p04465466-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/community-acquired-methicillin-resistant-staphylococcus-aureus-ca-mrsa-infections---pipeline-review-h2-2016-300380420.html


'/>"/>
SOURCE Reportlinker
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Community Pharmacy Goes Digital
2. Life Technologies and RainTree Oncology Services Announce Collaboration to Bring Molecular Tumor Testing to Community Oncologists
3. Community Pharmacies Are Effective Locations for Rapid HIV Testing
4. Cardinal Health Makes It Easier For Community Pharmacies To Help Patients Access, Improve Compliance With Specialty Medications
5. Cepheid Launches Mobile Community for Ride Against TB Campaign to Benefit the American Lung Association
6. Southeast Michigan Beacon Community to Integrate Laboratory Tests from Quest Diagnostics Into BeaconLink2Health Health Information Exchange
7. Larkin Community Hospital Hosts International Dental Teaching Symposium
8. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
9. DSI Northeast Phoenix Dialysis Hosts Community Open House Event
10. RainTree Oncology Expands Management As Strategic Vision For Community Oncology Unfolds
11. GlaxoSmithKline, Community Care of North Carolina harness "small data" to improve patient care and reduce health care costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2018)... ... August 07, 2018 , ... ... the role of Sanarus Technologies President, effective immediately. Mr. Stark will lead ... sales experience in medical device toward finding new and innovative ways to ...
(Date:8/3/2018)... ... August 03, 2018 , ... LifeWIRE’s ... ACT patents list of the 5,000-strong association of app companies and information technology ... Self-Management Compliance and Notification Method System and Computer Program Product” and subsequent patents ...
(Date:8/2/2018)... ... August 02, 2018 , ... What: The Wharton School is pleased to ... will allow up to five business reporters who cover aspects of public policy to ... year. Each funding opportunity covers the cost of tuition, course materials, most group ...
Breaking Medicine Technology:
(Date:8/14/2018)... ... August 14, 2018 , ... Eagle Merchant ... a leading provider of residential and commercial recreational surfacing products across the country. ... with products used across a wide range of markets and customers. Founded in ...
(Date:8/11/2018)... ... ... Johns Hopkins All Children’s Hospital will make a broader commitment to ensuring ... perspective on care. At its core, this perspective focuses on ways to improve health ... or setting at the right cost. Mark Douglas "Doug" Baker, M.D., will focus on ...
(Date:8/9/2018)... SEATTLE (PRWEB) , ... August 09, 2018 , ... Lyme ... cases reported per year skyrocketing to an estimated 329,000 – a 25-fold increase since ... Trends™ , Lyme disease can be found all 50 states and the District of ...
(Date:8/9/2018)... ... August 09, 2018 , ... Thanks to the generosity of ... distributors, customers, and employees, the newly established Isagenix Legacy Foundation raised ... goal. 100 percent of the donations will fund grants to nonprofit organizations that ...
(Date:8/7/2018)... ... August 07, 2018 , ... The American ... selected to receive the 2018 Board of Directors Student Scholarship . The ... of psychiatric-mental health nursing and develop the next generation of leaders in the ...
Breaking Medicine News(10 mins):